Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : 67Cu-based Therapy
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : NUCLIDIUM
Deal Size : Undisclosed
Deal Type : Partnership
NUCLIDIUM and Guerbet Form Strategic Partnership for Copper-based Radiotheranostics
Details : NUCLIDIUM and Guerbet will support the advancement of targeted copper-based radiotheranostics, 61Cu-based NuriPro, which binds specifically to PSMA, for the treatment of prostate cancer.
Brand Name : NuriPro
Molecule Type : Small molecule
Upfront Cash : Undisclosed
May 22, 2024
Lead Product(s) : 67Cu-based Therapy
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : NUCLIDIUM
Deal Size : Undisclosed
Deal Type : Partnership
LOOKING FOR A SUPPLIER?